Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk. The design starts with about 80 randomized patients and, if continuation criteria are met, expands to roughly 608 patients total — potentially shrinking the planned program from ~1,500 patients to ~600, a reduction of about 60%. Medicus explicitly does not intend to fund execution itself; if FDA feedback is constructive it will seek to out-license or partner the program rather than commit internal capital.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.